- Company
- Kyowa Kirin·Boryung to copromote sale of 2 neutropenia txs
- by Chon, Seung-Hyun Mar 4, 2022 05:55am
- Boryung Pharmaceutical and Kyowa Kirin Korea will be jointly selling 2 types of neutropenia treatments in Korea. On the 2nd, Kyowa Kirin Korea and Boryung Pharmaceutical announced that the companies signed a co-promotion agreement to jointly sell the neutropenia treatments ‘Grasin (filgrastim)’ and ‘Neulasta (pegfilgrastim)’ in Kore
- Company
- Saxenda and Qsymia tops the growing obesity market
- by Chon, Seung-Hyun Mar 3, 2022 06:01am
- The obesity treatment market has grown to break its own record for 3 consecutive years. The introduction of a new type of obesity treatment such as ‘Saxenda’ and ‘Qsymia’ had also led to market expansion.’ The two drugs have dominated the share of existing products and have occupied about half of the total market. According to market res
- Company
- BRAF I Braftovi can be prescribed at the Big 5
- by Eo, Yun-Ho Mar 3, 2022 06:01am
- Along with the progress of the insurance benefit procedure, "Braftovi," which lowers the BRAF, will be prescribed at general hospitals. According to related industries, Braftovi (Encorafenib), a treatment for colorectal cancer in Ono Pharmaceutical Industry, passed the Pharmaceutical Affairs Committee (DC) of Korea University Anam Hospita
- Company
- Entresto settles in as early-stage heart failure treatment
- by Eo, Yun-Ho Mar 3, 2022 06:01am
- The heart failure treatment ‘Entresto’ will now be covered by insurance benefits in the first line as well. According to industry sources, reimbursement for Novartis Korea’s chronic heart failure treatment ‘Entresto (sacubitril)’ will be expanded to cover patients with acute decompensated heart failure who are in a stable hemodynamic
- Company
- Omicron confirmed cases continue to occur in companies
- by Ji Yong Jun Mar 2, 2022 05:55am
- Due to the spread of COVID-19 Omicron, there are a series of in-house confirmed cases within pharmaceutical bio companies. Pharmaceutical bio companies are responding by operating the Omicron emergency system and granting additional telecommuting to close contacts. According to the Central Disease Control Headquarters on the 2nd, the numbe
- Company
- Keytruda may make ₩300 billion with 1st-line reimb
- by Mar 2, 2022 05:55am
- The reimbursement expansion approval of Keytruda is expected to add wings to the sales growth of an already leading product in the domestic pharmaceutical market. It is expected that the company may achieve &8361;300 billion in sales with its reimbursement expansion to the first-line, which has more patients, from the &8361;200 billion sol
- Company
- Tylenol's sales amounted to ₩83.1 billion last year
- by Chon, Seung-Hyun Mar 2, 2022 05:54am
- OTC Tylenol recorded the highest sales ever. Sales more than doubled last year from the previous year due to a surge in demand for COVID-19 vaccinations. However, growth slowed in the second half of last year as demand for Tylenol was resolved. According to IQVIA, a pharmaceutical research institute, sales of the Tylenol series last year amou
- Company
- Pfizer's 3rd attempt to reimburse ATTR-CM drug ‘Vyndamax'
- by Eo, Yun-Ho Feb 28, 2022 05:55am
- The third attempt at reimbursement for Vyndamax, a new drug for transthyretin amyloid cardiomyopathy, has been made by its company. According to industry sources, Pfizer Korea had again applied for the insurance reimbursement of its new drug that is indicated for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). This is t
- Company
- Osteoporosis should be taken care of for the rest of life
- by Feb 28, 2022 05:55am
- The Korean Society for Bone and Mineral Research has begun to improve awareness of osteoporosis treatment. This is to enable continuous treatment by recognizing the seriousness of diseases that can lead to death from fractures and improving standards. Osteoporosis is a disease in which holes are formed in bones, and when bone strength weak
- Company
- Moderna and BeiGene joined KRPIA
- by Eo, Yun-Ho Feb 25, 2022 05:57am
- According to related industries, U.S.-Moderna Korea and Chinese-BeiGene Korea recently joined as KRPIA members. As a result, the number of KRPIA member companies has increased to 46. Both Moderna and BeiGene are multinational pharmaceutical companies that established a Korean subsidiary last year, and promotional activities are expected to
